AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 81 min read$IDYA

Hata Yujiro S sold $985K of IDYA

Hata Yujiro S (President and CEO) sold 26,338 shares of IDEAYA Biosciences, Inc. (IDYA) at an average of $37.41 ($37.39–$38.26, $0.99M total) across 2 trades on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hata Yujiro S
Published Oct 8, 2026, 11:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IDYA
Bearish
medium confidence
Mentioned
$IDYA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IDYABearishLow
01

Why it matters

The transaction reduces insider ownership and may be interpreted as a lack of confidence, prompting short‑term price pressure.

02

Market read

A fresh insider sale of nearly $1M by the CEO, reported via a Form 4 filing, provides new data for traders.

03

What to watch

Potential upcoming clinical data releases or financing needs that prompted the sale.

Relevance 4/10Novelty 4/10Timing: post‑market today

Background

Form 4 filing discloses a recent open‑market sale by IDEAYA Biosciences' CEO.

Company-level read

Ticker impact

$IDYABearishMedium confidence
Context

CEO Hata Yujiro S sold 26,338 shares for $985K via a 10b5-1 plan, reducing his stake to 690,695 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

The sale is sizable for a micro‑cap and executed through a pre‑arranged plan, which often triggers short‑term sell‑off.

Market effects

Sector

Minimal impact on the broader biotech sector; insider sales are company‑specific.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale could be routine under a 10b5‑1 plan and not reflect negative sentiment.

Key entities

  • Company
    IDEAYA Biosciences, Inc.

    Biotech firm listed on Nasdaq (IDYA).

  • Person
    Hata Yujiro S

    President, CEO, and Director of IDEAYA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IDYA insider trading history →

Related articles

OCT 19
$IDYAMedAI 8/10

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

IDEAYA Biosciences and Servier presented clinical trial data at ESMO 2026, showing positive results for darovasertib in treating uveal melanoma. OptimUM-01 data showed 7.4-month PFS and 27.1-month mOS in treatment-naïve patients. OptimUM-02 data confirmed improvements in ORR and PFS across subgroups. OptimUM-09 data demonstrated 57% eye preservation rate and 66% radiation dose reduction in primary UM patients.

prnewswire.com2 min
SEP 25
$IDYAMedAI 8/10

Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?

IDEAYA Biosciences (IDYA) reported a widened quarterly net loss but maintains strong liquidity with $1.24B in cash. It dosed the first patient in a Phase 3 trial for darovasertib in uveal melanoma, sharing costs with partner Servier. The company is advancing its oncology pipeline while managing R&D costs, with regulatory approvals and commercial execution being key to its success.

insidermonkey.com3 min